Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,3165,340,28
Msft0,47
Nokia3,76053,85950,41
IBM0,66
Mercedes-Benz Group AG72,6872,7-0,55
PFE-0,31
10.06.2023 2:04:00
Indexy online
AD Index online
select
AD Index online
 

BioAlliance
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 10.06.2023
Popis společnosti
Obecné informace
Název společnostiOnxeo SA
TickerALVIO
Kmenové akcie:Ordinary Shares
RICALVIO.PA
ISINFR0010095596
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky31.12.2022
Počet zaměstnanců k 31.12.2022 25
Akcie v oběhu k 31.12.2022 110 931 433
MěnaEUR
Kontaktní informace
Ulice49 boulevard du General Martial Valin
MěstoPARIS
PSČ75015
ZeměFrance
Kontatní osoba 
Funkce kontaktní osoby 
Telefon33 145 587 600
Fax33145580881

Business Summary: Onxeo SA, formerly Bioalliance Pharma SA, is a France-based biopharmaceutical company. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. It has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. It also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2022, Onxeo SA revenues decreased 64% to EUR1.4M. Net loss applicable to common stockholders increased from EUR5.9M to EUR19.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects R&D costs increase from EUR3.1M to EUR7.9M (expense), Cost of net financial debt increase from EUR848K to EUR2.2M (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 10.06.2023
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorShefali Agarwal4907.04.202207.04.2022
Chief Financial Officer, Member of the Executive CommitteeNicolas Fellman50
Director of Human Resources, Member of the Executive CommitteeAudrey Legentil-Dumery-10.02.201510.02.2015
Chief Medical Officer, Member of the Executive CommitteeOlivier De Beaumont-01.03.201701.03.2017